96 Kensington High Street
16 articles with MiNA Therapeutics
MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation.
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
MiNA Therapeutics Announces Enrolment of Patients in Expansion of Phase Ib Trial Evaluating MTL-CEBPA in Combination with Sorafenib
MiNA Therapeutics, announced enrolment of the first patients treated with MTL-CEBPA in combination with Sorafenib in OUTREACH, the multi-centre Phase 1b clinical trial in patients with advanced liver cancer.
MiNA Therapeutics remains on track with current development plans for small activating RNA medicines including clinical development of MTL-CEBPA drug candidate
MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
Oral presentation by trial’s Chief Investigator describes complete tumour responses reported in patients off-study when subsequently administered standard of care
MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients
MiNA Therapeuticstoday announced preliminary results from its ongoing Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in advanced liver cancer.
MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease
Data published in oncogene demonstrate improvement of liver function and increased survival in multiple disease models
11/27/2017Boehringer has made a big push into RNA this month.
Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.
The grant of up to approximately £400,000, with additional funding from MiNA and LGC LINK, will support a two-year research project.
MiNA Announces Publication Of Pre-Clinical Data Supporting On-Target Mechanism Of Action Of Clinical Candidate MTL-CEBPA
MiNA Presents Data Demonstrating Survival Benefit Of MTL-CEBPA In Animal Model Of Liver Failure At AASLD Liver Meeting
MiNA Announces Presentation Of Pre-Clinical Data Supporting On-Target Mechanism Of Action Of Clinical Candidate MTL-CEBPA